Therefore, DPPIV inhibitors might promote glucoregulation in part because of resulting elevated levels of PYY 1-36 , albeit with associated losses in food intake and body weight reduction
This research offers further insight into this emerging safety signal, according to the study authors who noted in their Ophthalmology paper, Our novel, stratified analysis provides a more nuanced interpretation than previous pooled reviews, isolating a potential increased risk signal to observational data in the diabetes population only, a finding not corroborated by RCTs. These results are somewhat at odds with the narrative surrounding GLP-1 use and NAION risk that began in early 2024, but the researchers say they are confident in their methodology
If the main driver is laxity, a procedure that heats the dermis can match the goal better than a serum alone
The ASMBS study found that as many as 70% of patients discontinue GLP-1 treatment within one year
Signs of allergic reaction: Difficulty breathing, swelling of the face or throat, widespread hives, or a rapid heart rate
It is different from other peptides in that it does not stimulate Gherlin, the hormone responsible for hunger